[ad_1]
Therapeutic Crispr The stock (CRSP) catapulted higher on Monday after biotechnology announced that it had given its patient its CRISPR gene modification therapy, making it the first company to use this technology in a study. clinical.
X
Today, in the stock market, shares of Crispr jumped 25.2% to 39.65. Shares of his partner, Vertex Pharmaceuticals (VRTX), increased by a fraction.
The patient received CTX001, a CRISPR gene modification therapy tested in beta-thalassemia in Europe. Crispr and Vertex also test CTX001 in the United States in patients with sickle cell disease. The first patient in this study will receive the CRISPR gene editing treatment by mid-2019.
"We have made tremendous progress with the CTX001," said Samarth Kulkarni, chief executive of Crispr, in a statement.
The news has exploded other biotech actions. Editas Medicine (EDIT) and Therapeutic Intellia (NTLA) shares rose 5.3% and 6.1%, respectively, at closing. Both biotechnology companies are working on CRISPR gene editing therapies.
YOU COULD ALSO LIKE:
Top 5 Biotech Values Have Growth Problems – Some Are Immune?
Which pharmaceutical actions outperform all other actions?
Danaher to acquire GE Biopharma segment as part of $ 21.4 billion takeover
[ad_2]
Source link